<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Belimumab</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08879</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (<span class="caps">SLE</span>). More specifically, it is a fully human recombinant monoclonal IgG antibody and it is the first biological treatment approved for the indication of <span class="caps">SLE</span>. Concomitant use with live or inactivated vaccines must be avoided. Belimumab was <span class="caps">FDA</span> approved on March 9, 2011.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C <sub>6358</sub> H <sub>9904</sub> N <sub>1728</sub> O <sub>2010</sub> S <sub>44</sub></td></tr><tr><th>Protein average weight</th><td>147 kDa </td></tr><tr><th>Sequences</th><td></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Benlysta </td><td>Human Genome Sciences Inc.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/monoclonal-antibodies">Monoclonal antibodies</a></li></ul></td></tr><tr><th>CAS number</th><td>356547-88-1</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Adjunct treatment for auto-antibody-positive active systemic lupus erythematosus. </td></tr><tr><th>Pharmacodynamics</th><td>By the 52nd week of treatment with belimumab, a reduction in CD19+, CD20+, naive and activated B cells, plasma cells, plasmacytoid cells, and SLE B-cell subset can be observed. Reductions in plasma cells and SLE B-cell subset can be seen by the eighth week and these levels were maintained to week 52. Belimumab also reduced levels of IgG and anti-dsDNA.</td></tr><tr><th>Mechanism of action</th><td>Belimumab selectively binds to soluble human B lymphocyte stimulator protein (BLyS) so that BLyS is unable to bind to receptors on B lymphocytes. The binding of BLyS to its receptor is essential for the survival of B lymphocytes. Consequently, belimumab reduces B-cell mediated immunity and the autoimmune response.
</td></tr><tr><th>Absorption</th><td>Cmax, 10 mg/kg, SLE patients = 313 &#181;g/mL; AUC (0-&#8734;), 10 mg/kg, SLE patients = 3083.</td></tr><tr><th>Volume of distribution</th><td><p>Vdss, 10 mg/kg, <span class="caps">SLE</span> patients = 5.29 L.</p></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Because belimumab is a protein, it is expected that it is degraded into peptides and amino acids by proteolytic enzymes.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Terminal elimination half-life, 10 mg/kg, SLE patients= 19.4 days; Distribution half-life, 10 mg/kg, SLE patients = 1.75 days.</td></tr><tr><th>Clearance</th><td><p>Systemic clearance, 10 mg/kg, <span class="caps">SLE</span> patients = 215 mL/day.</p></td></tr><tr><th>Toxicity</th><td>The most commonly-reported adverse reactions, occurring in &#8805;5% of patients in clinical trials were nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. The most common serious adverse reactions were serious infections.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, lyophilized, for solution</td><td>Intravenous</td><td>120 mg, 400 mg</td></tr></tbody></table></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB05773">ado-trastuzumab emtansine</a></td><td>Avoid combination due to the increased risk of belimumab associated side effects.


</td></tr><tr><td><a href="/drugs/DB06681">Belatacept</a></td><td>Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. </td></tr><tr><td><a href="/drugs/DB06643">Denosumab</a></td><td>Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. </td></tr><tr><td><a href="/drugs/DB08868">Fingolimod</a></td><td>Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. </td></tr><tr><td><a href="/drugs/DB06674">golimumab</a></td><td>Avoid combination with belimumab due to the increased chance of belimumab associated side effects.

</td></tr><tr><td><a href="/drugs/DB01005">Hydroxyurea</a></td><td> Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>